Role of next-generation sequencing in revolutionizing healthcare for cancer management

Abstract

Next-generation sequencing (NGS) has emerged as a transformative technology in oncology, revolutionizing cancer diagnostics and personalized treatment strategies. By providing comprehensive insights into the genetic landscape of tumors, NGS enables the identification of critical somatic and germline mutations, copy number variations (CNVs), and gene fusions. Over the past decade, advancements in NGS platforms have led to greater accuracy, speed, and cost-effectiveness, making it an integral part of cancer research and clinical diagnostics. Despite its widespread adoption, significant challenges remain, including the need for improved methods to detect minimal residual disease (MRD) and accurately profile tumor heterogeneity. This review explores the evolution of NGS technologies and their pivotal role in cancer biology, from early diagnostics to therapeutic guidance. It delves into the application of NGS in identifying CNVs and gene fusions, monitoring MRD, and the increasing relevance of targeted NGS and spatial genomics. Furthermore, the integration of spatial transcriptomics is highlighted as a frontier in understanding the tumor microenvironment. By addressing these critical aspects, this review provides a comprehensive overview of how NGS is shaping the future of cancer research and treatment, offering a complete overview of potential NGS applications in scientific and clinical oncology.

Keywords

genomics / next generation sequencing / oncology / single cell RNA sequencing / spatial transcriptomics

References

[1] WetterstrandK. DNA Sequencing Costs: data from the NHGRI genome sequencing program (GSP). National Human Genome Research Institute [online]. 2016. http://www.genome.gov/sequencingcosts

[2] MarguliesM, EgholmM, AltmanWE, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature. 2005;437(7057):376-380.

[3] MinocheAE, DohmJC, HimmelbauerH. Evaluation of genomic high-throughput sequencing data generated on illumina HiSeq and genome analyzer systems. Genome Biol. 2011;12:R112.

[4] Sikkema-RaddatzB, Johansson LF, de BoerEN, et al. Targeted next-generation sequencing can replace sanger sequencing in clinical diagnostics. Hum Mutat. 2013;34(7):1035-1042.

[5] RothbergJM, LeamonJH. The development and impact of 454 sequencing. Nature Biotechnol. 2008;26(10):1117-1124.

[6] CoxMP, Peterson DA, BiggsPJ. SolexaQA: at-a-glance quality assessment of illumina second. BMC Bioinform. 2010;11:485.

[7] RothbergJM, HinzW, RearickTM, et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature. 2011;475(7356):348-352.

[8] EidJ, FehrA, GrayJ, et al. Real-time DNA sequencing from single polymerase molecules. Science. 2009;323(5910):133-138.

[9] ClarkeJ, WuHC, JayasingheL, Patel A, ReidS, BayleyH. Continuous base identification for single-molecule nanopore DNA sequencing. Nature Nanotechnol. 2009;4(4):265-270.

[10] KanziAM, SanJE, ChimukangaraB, et al. Next generation sequencing and bioinformatics analysis of family genetic inheritance. Front Genet. 2020;11(October):1-18.

[11] GoodwinS, McPherson JD, McCombieWR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17(6):333-351.

[12] VinkšelM, WritzlK, MaverA, Peterlin B. Improving diagnostics of rare genetic diseases with NGS approaches. J Community Genet. 2021;12(2):247-256.

[13] MantereT, Kersten S, HoischenA. Long-read sequencing emerging in medical genetics. Front Genet. 2019;10(May):1-14.

[14] GullapalliRR, DesaiKV, Santana-SantosL, KantJA, BecichMJ. Next generation sequencing in clinical Medicine: challenges and lessons for pathology and biomedical informatics. J Pathol Inform. 2012;3(1):40.

[15] KruglyakKM, LinE, OngFS. Next-generation sequencing in precision oncology: challenges and opportunities. Expert Rev Mol Diagn. 2014;14(6):635-637.

[16] PurnamaU, Castro-Guarda M, SahooOS, CarrCA. Modelling diabetic cardiomyopathy: using human stem cell-derived cardiomyocytes to complement animal models. Metabolites. 2022;12(9):832.

[17] SahaB, RoyA, BeltramoE, Sahoo OS. Stem cells and diabetic retinopathy: from models to treatment. Mol Biol Rep. 2023;50(5):4517-4526.

[18] SagoH, Sekizawa A. Nationwide demonstration project of next-generation sequencing of cell-free DNA in maternal plasma in Japan:1-year experience. Prenat Diagn. 2015;35(4):331-336.

[19] NakanoK, Shiroma A, ShimojiM, et al. Advantages of genome sequencing by long-read sequencer using SMRT technology in medical area. Hum Cell. 2017;30(3):149-161.

[20] ChenJ, ChengJ, ChenX, Inoue M, LiuY, SongCX. Whole-genome long-read TAPS deciphers DNA methylation patterns at base resolution using PacBio SMRT sequencing technology. Nucleic Acids Res. 2022;50(18):E104.

[21] YangF. Genome dynamics and diversity of shigella species, the etiologic agents of bacillary dysentery. Nucleic Acids Res. 2005;33(19):6445-6458.

[22] WuHJ, WangAHJ, JenningsMP. Discovery of virulence factors of pathogenic bacteria. Curr Opin Chem Biol. 2008;12(1):93-101.

[23] MaanssonM, VynneNG, KlitgaardA, et al. An integrated metabolomic and genomic mining workflow to uncover the biosynthetic potential of bacteria. mSystems. 2016;1(3):e00028-15.

[24] ParsonsDW, JonesS, ZhangX, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-1812.

[25] RaoA, Barkley D, FrançaGS, YanaiI. Exploring tissue architecture using spatial transcriptomics. Nature. 2021;596(7871):211-220.

[26] SahooOS, MitraR, NagaiahNKH. The hidden architects of glioblastoma multiforme: glioma stem cells. MedComm—Oncology. 2024;3(1):e66.

[27] TalukdarJ, Srivastava TP, SahooOS, et al., Cancer stem cells: signaling pathways and therapeutic targeting. MedComm-Oncology. 2023;2(4):e62.

[28] SahooOS, Pethusamy K, SrivastavaTP, et al. The metabolic addiction of cancer stem cells. Front Oncol. 2022;12(July):1-29.

[29] LarribèreL, Martens UM. Advantages and challenges of using ctDNA NGS to assess the presence of minimal residual disease (MRD) in solid tumors. Cancers. 2021;13(22):5698.

[30] LinC, LiuX, ZhengB, Ke R, TzengCM. Liquid biopsy, ctDNA diagnosis through NGS. Life. 2021;11(9):890.

[31] VosoMT, OttoneT, LavorgnaS, et al. MRD in AML: the role of new techniques. Front Oncol. 2019;9(July):1-10.

[32] ShiiharaM, Ishikawa T, SaikiY, et al. Development of a system combining comprehensive genotyping and organoid cultures for identifying and testing genotype-oriented personalised medicine for pancreatobiliary cancers. Eur J Cancer. 2021;148:239-250.

[33] NafeaAM, WangY, WangD, et al. Application of next-generation sequencing to identify different pathogens. Front Microbiol. 2024;14:1329330.

[34] Rajilic-StojanovicM, Figueiredo C, SmetA, et al. Systematic review: gastric microbiota in health and disease. Aliment Pharmacol Ther. 2020;51(6):582-602.

[35] BhattacharjeeA, SahooOS, SarkarA, et al. Infiltration to infection: key virulence players of helicobacter pylori pathogenicity. Infection. 2024;52:345-384.

[36] Om Saswat SahooS, Dhar R, Arun KumarK, SubhradipK. Challenges and lessons from COVID-19. Asian J Med Sci. 2023;14(7):265-267.

[37] SahooOS, Pethusamy K, NayekA, MinochaR, DharR, KarmakarS. Paradigm of immune dysregulation in coronavirus disease-2019 infection. Exploration Immunol. 2024;4(1):1-33.

[38] Méndez-SalazarEO, Ortiz-LópezMG, Granados-Silvestre MÁ, et al. Corrigendum: altered gut microbiota and compositional changes in firmicutes and proteobacteria in Mexican undernourished and obese children. Front Microbiol. 2018;9(OCT):1-11.

[39] SatamH, JoshiK, MangroliaU, et al. Next-Generation sequencing technology: current trends and advancements. Biology. 2023;12:997.

[40] ChenZ, GuanD, WangZ, et al. Microbiota in cancer: molecular mechanisms and therapeutic interventions. MedComm. 2023;4(6):1-44.

[41] YangM, KimJW. Principles of genetic counseling in the era of next-generation sequencing. Ann Lab Med. 2018;38(4):291-295.

[42] SongX, HuY, LiY, ShaoR, LiuF, LiuY. Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther. 2020;5(1):230.

[43] BørstingC, Morling N. Next generation sequencing and its applications in forensic genetics. Forensic Sci Int: Genet. 2015;18:78-89.

[44] McCormackJE, HirdSM, ZellmerAJ, Carstens BC, BrumfieldRT. Applications of next-generation sequencing to phylogeography and phylogenetics. Mol Phylogenet Evol. 2013;66(2):526-538.

[45] EkblomR, Galindo J. Applications of next generation sequencing in molecular ecology of non-model organisms. Heredity. 2011;107(1):1-15.

[46] AfzalM, Alghamdi SS, MigdadiHH, et al. Legume genomics and transcriptomics: from classic breeding to modern technologies. Saudi J Biol Sci. 2020;27(1):543-555.

[47] ThottathilGP, Jayasekaran K, OthmanAS. Sequencing crop genomes: a gateway to improve tropical agriculture. Trop Life Sci Res. 2016;27(1):93-114.

[48] VarshneyRK, NayakSN, MayGD, Jackson SA. Next-generation sequencing technologies and their implications for crop genetics and breeding. Trends Biotechnol. 2009;27(9):522-530.

[49] ParkDG, KwonJG, HaES, et al. Novel next generation sequencing panel method for the multiple detection and identification of foodborne pathogens in agricultural wastewater. Front Microbiol. 2023;14(July):1179934.

[50] OkamotoN, MiyaF, TsunodaT, et al. Targeted next-generation sequencing in the diagnosis of neurodevelopmental disorders. Clin Genet. 2015;88(3):288-292.

[51] LiJ, WangL, GuoH, et al. Targeted sequencing and functional analysis reveal brain-size-related genes and their networks in autism spectrum disorders. Mol Psychiatry. 2017;22(9):1282-1290.

[52] BasuC, PerlSM. The use of RNA-seq for the study of physiological adaptations of halophiles in extreme environments for astrobiological data interpretation. Front Astron Space Sci. 2024;11(March):1-8.

[53] CarrCE, Mojarro A, TaniJ, et al. Advancing the search for extra-terrestrial genomes. IEEE Aerosp Conf Proc. 2016.

[54] BashirAK, WinkL, DullerS, et al. Taxonomic and functional analyses of intact microbial communities thriving in extreme, astrobiology-relevant, anoxic sites. Microbiome. 2021;9:50.

[55] RabbaniB, Mahdieh N, HosomichiK, NakaokaH, InoueI. Next-generation sequencing: impact of exome sequencing in characterizing mendelian disorders. J Hum Genet. 2012;57(10):621-632.

[56] ZhaoS, ZhangC, MuJ, et al. All-in-one sequencing: an improved library preparation method for cost-effective and high-throughput next-generation sequencing. Plant Methods. 2020;16(1):74.

[57] ParkST, KimJ. Trends in next-generation sequencing and a new era for whole genome sequencing. Int Neurourol J. 2016;20:S76-S83.

[58] NevesLG, DavisJM, BarbazukWB, Kirst M. Whole-exome targeted sequencing of the uncharacterized pine genome. Plant J. 2013;75(1):146-156.

[59] Blanco-MíguezA, Beghini F, CumboF, et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nature Biotechnol. 2023;41(11):1633-1644.

[60] HolleyRW, ApgarJ, EverettGA, et al. Structure of a ribonucleic acid. Science. 1965;147(3664):1462-1465.

[61] HeatherJM, ChainB. The sequence of sequencers: the history of sequencing DNA. Genomics. 2016;107(1):1-8.

[62] BarbaM, Czosnek H, HadidiA. Historical perspective, development and applications of next-generation sequencing in plant virology. Viruses. 2014;6(1):106-136.

[63] XiaoM, ZhangY, ChenX, et al. Transcriptome analysis based on next-generation sequencing of non-model plants producing specialized metabolites of biotechnological interest. J Biotech. 2013;166(3):122-134.

[64] HuT, Chitnis N, MonosD, DinhA. Next-generation sequencing technologies: an overview. Hum Immunol. 2021;82(11):801-811.

[65] SatamH, JoshiK, MangroliaU, et al. Next-Generation sequencing technology: current trends and advancements. Biology. 2023;12(7):997.

[66] MiraflorAP, de Abreu FB, PetersonJD, et al. Somatic mutation analysis in melanoma using targeted next generation sequencing. Exp Mol Pathol. 2017;103(2):172-177.

[67] SwierniakM, Pfeifer A, StokowyT, et al. Somatic mutation profiling of follicular thyroid cancer by next generation sequencing. Mol Cell Endocrinol. 2016;433:130-137.

[68] GiardinaT, Robinson C, Grieu-IacopettaF, et al. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice. Pathology. 2018;50(4):389-401.

[69] SpencerDH, ZhangB, PfeiferJ. Single Nucleotide Variant Detection Using Next Generation Sequencing. Elsevier Inc; 2015.

[70] BrunoR, Fontanini G. Next generation sequencing for gene fusion analysis in lung cancer: a literature review. Diagnostics. 2020;10(8):521.

[71] WangQ, XiaJ, JiaP, PaoW, ZhaoZ. Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives. Brief Bioinform. 2013;14(4):506-519.

[72] PodnarJ, Deiderick H, HuertaG, Hunicke-SmithS. Next-generation sequencing RNA-Seq library construction. Curr Protoc Mol Biol. 2014;106(SUPL.106):1-19.

[73] AroraI, Tollefsbol TO. Computational methods and next-generation sequencing approaches to analyze epigenetics data: profiling of methods and applications. Methods. 2021;187(July 2020):92-103.

[74] LeeS, KimJ. NGS-based deep bisulfite sequencing. MethodsX. 2016;3:1-7.

[75] ParkPJ. ChIP-seq: advantages and challenges of a maturing technology. Nat Rev Genet. 2009;10(10):669-680.

[76] GolanT, HammelP, ReniM, et al. Maintenance olaparib for germline BRCA -mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317-327.

[77] MateoJ, PortaN, BianchiniD, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):162-174.

[78] SangkuhlK, Whirl-Carrillo M, WhaleyRM, et al. Pharmacogenomics clinical annotation tool (PharmCAT). Clin Pharm Ther. 2020;107(1):203-210.

[79] DuanJ, ZhangJG, DengHW, Wang YP. Comparative studies of copy number variation detection methods for next-generation sequencing technologies. PLoS One. 2013;8(3):e59128.

[80] QuenezO, Cassinari K, CoutantS, et al. Detection of copy-number variations from NGS data using read depth information: a diagnostic performance evaluation. Eur J Human Genet. 2021;29(1):99-109.

[81] VaishnaviA, LeAT, DoebeleRC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25-34.

[82] SantosJN, Sousa Neto ES, FrançaJA, et al. Next-generation sequencing of oncogenes and tumor suppressor genes in odontogenic myxomas. J Oral Pathol Med. 2017;46(10):1036-1039.

[83] WangL, Babikir H, MüllerS, et al. The phenotypes of proliferating glioblastoma cells reside on a single axis of variation. Cancer Discov. 2019;9(12):1708-1719.

[84] HadidiA. Next-generation sequencing and CRISPR/Cas13 editing in viroid research and molecular diagnostics. Viruses. 2019;11(2):120.

[85] SelvakumarSC, Preethi KA, RossK, et al. CRISPR/Cas9 and next generation sequencing in the personalized treatment of cancer. Mol Cancer. 2022;21(1):83.

[86] ZhouL, YaoS. Recent advances in therapeutic CRISPR-Cas9 genome editing: mechanisms and applications. Molecular Biomed. 2023;4(1):10.

[87] XieZ, ZhouZ, YangS, Zhang S, ShaoB. Epigenetic regulation and therapeutic targets in the tumor microenvironment. Molecular Biomed. 2023;4(1):17.

[88] LiuL, LiuJ, ShaoD, et al. Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients. Cancer Sci. 2017;108(12):2487-2494.

[89] RossJS, BadveS, WangK, et al. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options. Arch Pathol Lab Med. 2015;139(5):642-649.

[90] RossJS, AliSM, WangK, et al. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecol Oncol. 2013;130(3):554-559.

[91] HofmanP, DenisMG. The use of minimal residual disease in thoracic oncology: gaps between promises and the on-the-ground reality of daily practice. Cytopathology. 2024;35(1):7-15.

[92] ShortNJ, Kantarjian H, RavandiF, et al. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022;6(13):4006-4014.

[93] TsaiCH, TangJL, TienFM, et al. Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML. Blood Adv. 2021;5(10):2456-2466.

[94] TarazonaN, Gimeno-Valiente F, GambardellaV, et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol. 2019;30(11):1804-1812.

[95] MalhotraD, SebatJ. CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell. 2012;148(6):1223-1241.

[96] PolyakK. Heterogeneity in breast cancer. J Clin Invest. 2011;121(10):3786-3788.

[97] TreangenTJ, Salzberg SL. Repetitive DNA and next-generation sequencing: computational challenges and solutions. Nat Rev Genet. 2012;13(1):36-46.

[98] RacaG, Astbury C, BehlmannA, et al. Points to consider in the detection of germline structural variants using next-generation sequencing: A statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023;25(2):100316.

[99] ShlienA, MalkinD. Copy number variations and cancer. Genome Med. 2009;1(6):62.

[100] SerratìS, de Summa S, PilatoB, et al. Next-generation sequencing: advances and applications in cancer diagnosis. Onco Targets Ther. 2016;9:7355-7365.

[101] MitelmanF, Johansson B, MertensF. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nature Genet. 2004;36(4):331-334.

[102] AnnalaMJ, ParkerBC, ZhangW, Nykter M. Fusion genes and their discovery using high throughput sequencing. Cancer Lett. 2013;340(2):192-200.

[103] HeyerEE, Blackburn J. Sequencing strategies for fusion gene detection. BioEssays. 2020;42(7):1-11.

[104] LuthraR, ChenH, Roy-ChowdhuriS, SinghR. Next-generation sequencing in clinical molecular diagnostics of cancer: advantages and challenges. Cancers. 2015;7(4):2023-2036.

[105] WeiratherJL, AfsharPT, ClarkTA, et al. Characterization of fusion genes and the significantly expressed fusion isoforms in breast cancer by hybrid sequencing. Nucleic Acids Res. 2015;43(18):e116.

[106] SussmanRT, OranAR, PaolilloC, Lieberman D, MorrissetteJJD, RosenbaumJN. Validation of a next-generation sequencing assay targeting RNA for the multiplexed detection of fusion transcripts and oncogenic isoforms. Arch Pathol Lab Med. 2020;144(1):90-98.

[107] YuanJ, Takeuchi M, NegishiM, OguroH, Ichikawa H, IwamaA. Bmi1 is essential for leukemic reprogramming of myeloid progenitor cells. Leukemia. 2011;25(8):1335-1343.

[108] MartensJHA, Stunnenberg HG. The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett. 2010;584(12):2662-2669.

[109] DupainC, Harttrampf AC, UrbinatiG, GeoergerB, Massaad-Massade L. Relevance of fusion genes in pediatric cancers: toward precision Medicine. Mol Ther Nucleic Acids. 2017;6(March):315-326.

[110] SaitoM, Shiraishi K, KunitohH, TakenoshitaS, YokotaJ, KohnoT. Gene aberrations for precision Medicine against lung adenocarcinoma. Cancer Sci. 2016;107(6):713-720.

[111] CardonaAF, Arrieta O, Ruiz-PatiñoA, et al. Precision Medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries. Ther Adv Respir Dis. 2020;14:1-16.

[112] HeydariAA, SindiSS. Deep learning in spatial transcriptomics: learning from the next next-generation sequencing. Biophysics Rev. 2023;4(1):011306.

[113] SamorodnitskyE, JewellBM, HagopianR, et al. Evaluation of hybridization capture versus Amplicon-Based methods for whole-exome sequencing. Hum Mutat. 2015;36(9):903-914.

[114] SimonR, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discovery. 2013;12(5):358-369.

[115] SchenkD, SongG, KeY, WangZ. Amplification of overlapping DNA amplicons in a single-tube multiplex PCR for targeted next-generation sequencing of BRCA1 and BRCA2. PLoS One. 2017;12(7):e0181062.

[116] ZhangTH, WuNC, SunR. A benchmark study on error-correction by read-pairing and tag-clustering in amplicon-based deep sequencing. BMC Genom. 2016;17(1):108.

[117] PlagnolV, Woodhouse S, HowarthK, et al. Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling. PLoS One. 2018;13(3):e0193802.

[118] ChenZ, LiC, ZhouY, et al. Liquid biopsies for cancer: from bench to clinic. MedComm. 2023;4(4):1-24.

[119] OxnardGR, ThressKS, AldenRS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(28):3375-3382.

[120] SchrockAB, WelshA, ChungJH, et al. Hybrid Capture–Based genomic profiling of circulating tumor DNA from patients with advanced non–small cell lung cancer. J Thorac Oncol. 2019;14(2):255-264.

[121] NewmanAM, Bratman SV, ToJ, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Med. 2014;20(5):548-554.

[122] NewmanAM, Lovejoy AF, KlassDM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnol. 2016;34(5):547-555.

[123] HwangB, LeeJH, BangD. Single-cell RNA sequencing technologies and bioinformatics pipelines. Exp Mol Med. 2018;50(8):1-14.

[124] ChaoruiY, ZhuY, ChenM, et al Integration tools for scRNA-seq data and spatial transcriptomics sequencing data. Brief Funct Genom. 2024;23(4):295-302.

[125] van LeenE, Brückner L, HenssenAG. The genomic and spatial mobility of extrachromosomal DNA and its implications for cancer therapy. Nature Genet. 2022;54(2):107-114.

[126] AroraR, CaoC, KumarM, et al. Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response. Nat Commun. 2023;14(1):5029.

[127] ShengK, CaoW, NiuY, DengQ, ZongC. Effective detection of variation in single-cell transcriptomes using MATQ-seq. Nat Methods. 2017;14(3):267-270.

[128] van DijkEL, AugerH, JaszczyszynY, ThermesC. Ten years of next-generation sequencing technology. TIG. 2014;30(9):418-426.

[129] TangF, Barbacioru C, WangY, et al. mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods. 2009;6(5):377-382.

[130] HashimshonyT, WagnerF, SherN, Yanai I. CEL-Seq: Single-Cell RNA-Seq by multiplexed linear amplification. Cell Rep. 2012;2(3):666-673.

[131] HashimshonyT, Senderovich N, AvitalG, et al. CEL-Seq. 2: sensitive highly-multiplexed single-cell RNA-Seq. Genome Biol. 2016;17(1):77.

[132] ChoiJR, YongKW, ChoiJY, Cowie AC. Single-Cell RNA sequencing and its combination with protein and DNA analyses. Cells. 2020;9(5):1130.

[133] BagnoliJW, Ziegenhain C, JanjicA, et al. Sensitive and powerful single-cell RNA sequencing using mcSCRB-seq. Nat Commun. 2018;9(1):2937.

[134] RamsköldD, LuoS, WangYC, et al. Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nature Biotechnol. 2012;30(8):777-782.

[135] PicelliS, Björklund ÅK, FaridaniOR, SagasserS, Winberg G, SandbergR. Smart-seq. 2 for sensitive full-length transcriptome profiling in single cells. Nature Methods. 2013;10(11):1096-1098.

[136] AhmedR, ZamanT, ChowdhuryF, et al. Single-Cell RNA sequencing with spatial transcriptomics of cancer tissues. Int J Mol Sci. 2022;23(6):3042.

[137] MacoskoEZ, BasuA, SatijaR, et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell. 2015;161(5):1202-1214.

[138] CochainC, Vafadarnejad E, ArampatziP, et al. Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis. Circ Res. 2018;122(12):1661-1674.

[139] SkellyDA, Squiers GT, McLellanMA, et al. Single-Cell transcriptional profiling reveals cellular diversity and intercommunication in the mouse heart. Cell Rep. 2018;22(3):600-610.

[140] AspM, Bergenstråhle J, LundebergJ. Spatially resolved Transcriptomes—Next generation tools for tissue exploration. BioEssays. 2020;42(10):1-16.

[141] StåhlPL, Salmén F, VickovicS, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016;353(6294):78-82.

[142] JiAL, RubinAJ, ThraneK, et al. Multimodal analysis of composition and spatial architecture in human squamous cell carcinoma. Cell. 2020;182(2):497-514.e22.

[143] MoncadaR, Barkley D, WagnerF, et al. Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas. Nature Biotechnol. 2020;38(3):333-342.

[144] ChenKH, Boettiger AN, MoffittJR, WangS, ZhuangX. Spatially resolved, highly multiplexed RNA profiling in single cells. Science. 2015;348(6233):1360-1363.

[145] MoffittJR, HaoJ, Bambah-MukkuD, LuT, DulacC, ZhuangX. High-performance multiplexed fluorescence in situ hybridization in culture and tissue with matrix imprinting and clearing. Proc Natl Acad Sci. 2016;113(50):14456-14461.

[146] KeR, Mignardi M, HaulingT, NilssonM. Fourth generation of Next-Generation sequencing technologies: promise and consequences. Hum Mutat. 2016;37(12):1363-1367.

[147] SinghS, WangL, SchaffDL, et al. In situ 10-cell RNA sequencing in tissue and tumor biopsy samples. Sci Rep. 2019;9(1):4836.

[148] FoleyJW, ZhuC, JolivetP, et al. Gene expression profiling of single cells from archival tissue with laser-capture microdissection and Smart-3SEQ. Genome Res. 2019;29(11):1816-1825.

[149] VahrenkampJM, Szczotka K, DodsonMK, JarboeEA, Soisson AP, GertzJ. FFPEcap-seq: A method for sequencing capped RNAs in formalin-fixed paraffin-embedded samples. Genome Res. 2019;29(11):1826-1835.

[150] MortonML, BaiX, MerryCR, et al. Identification of mRNAs and lincRNAs associated with lung cancer progression using next-generation RNA sequencing from laser micro-dissected archival FFPE tissue specimens. Lung Cancer. 2014;85(1):31-39.

[151] CivitaP, Franceschi S, AretiniP, et al. Laser capture microdissection and RNA-seq analysis: high sensitivity approaches to explain histopathological heterogeneity in human glioblastoma FFPE archived tissues. Front Oncol. 2019;9(JUN):1-12.

[152] HuangD, MaN, LiX, et al. Advances in single-cell RNA sequencing and its applications in cancer research. J Hematol Oncol. 2023;16(1):98.

[153] AnderssonA, Bergenstråhle J, AspM, et al. Single-cell and spatial transcriptomics enables probabilistic inference of cell type topography. Commun Biol. 2020;3(1):565.

[154] RenX, ZhongG, ZhangQ, Zhang L, SunY, ZhangZ. Reconstruction of cell spatial organization from single-cell RNA sequencing data based on ligand-receptor mediated self-assembly. Cell Res. 2020;30(9):763-778.

[155] GyllborgD, Langseth CM, QianX, et al. Hybridization-based in situ sequencing (HybISS) for spatially resolved transcriptomics in human and mouse brain tissue. Nucleic Acids Res. 2020;48(19):E112.

[156] AspM, Giacomello S, LarssonL, et al. A spatiotemporal Organ-Wide gene expression and cell Atlas of the developing human heart. Cell. 2019;179(7):1647-1660.e19.

[157] ChenJ, SuoS, TamPP, Han JDJ, PengG, JingN. Spatial transcriptomic analysis of cryosectioned tissue samples with geo-seq. Nat Protoc. 2017;12(3):566-580.

[158] PengJ, SunBF, ChenCY, et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res. 2019;29(9):725-738.

[159] SchatzMC. Nanopore sequencing meets epigenetics. Nat Methods. 2017;14(4):347-348.

[160] Cretu StancuM, Van Roosmalen MJ, RenkensI, et al. Mapping and phasing of structural variation in patient genomes using nanopore sequencing. Nat Commun. 2017;8(1):1326.

[161] Gonzalez-GarayML. The road from next-generation sequencing to personalized medicine. Personalized Med. 2014;11(5):523-544.

[162] TripathiR, SharmaP, ChakrabortyP, VaradwajPK. Next-generation sequencing revolution through big data analytics. Front Life Sci. 2016;9(2):119-149.

[163] HamiltonR, Stephen S. Long-read sequencing for metagenomics in microbiology. In Diagnostic Molecular Pathology. 2nd ed. INC; 2024:39-48.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm - Future Medicine published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).